Sarah Walsh
Manager, Data Analytics & Evidence Synthesis
专长:
Sarah is a Manager on the Value & Evidence team at EVERSANA and provides statistical support and guidance on evidence synthesis projects.
Sarah brings over six years of academic experience and a strong background in research and data analysis. Since joining EVERSANA in November 2020, she has contributed to evidence synthesis projects in various disease areas such as oncology, rheumatology, and hematology. Her expertise focuses on the development and execution of ITC analyses including matching-adjusted indirect comparisons, network meta-analyses, meta-analyses, and inverse probability of treatment weighting. Sarah also has experience with targeted literature reviews and medical writing.
Prior to joining EVERSANA, she graduated from the University of Waterloo with a Master of Applied Mathematics (MMath). She has also completed a Bachelor of Science (BSc) from Cape Breton University with a major in mathematics and a minor in psychology.
Articles by Sarah Walsh
Evaluating PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Matching-Adjusted Indirect Comparison
Metastatic castration-resistant prostate cancer (mCRPC) is an incurable condition associated with poor prognosis and quality of life. Historically, patients with mCRPC had limited therapeutic options, and despite advancements in therapeutic innovation, the five-year relative survival rate for metastatic prostate cancer remains low (~34%). Encouragingly, multiple randomized clinical trials have recently demonstrated promising responses to novel […]
The Importance of Quality-of-Life Metrics in mCRPC
Prostate cancer is one of the most diagnosed malignancies in the world, with many patients progressing to an advanced stage of the disease called metastatic castration-resistant prostate cancer (mCRPC). Due to the poor prognosis and incurable nature of mCRPC, maintaining or improving quality of life (QoL) has become an important goal of therapy for patients, […]